Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
European Journal of Cancer · 2024-03 · 199 · 113555
DOI: 10.1016/j.ejca.2024.113555 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2024-03. Verfasst von Sara M Tolaney und 15 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: Sara_Tolaney@DFCI.HARVARD.EDU. Hauptthemen laut MEDLINE: Breast Neoplasms, Benzimidazoles. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: Sara_Tolaney@DFCI.HARVARD.EDU.
- Oncology2, Istituto Oncologico Veneto IRCCS, Padua, Italy.
- Korea University Guro Hospital, Seoul, Republic of Korea.
- Hospital Universitario de Canarias, Canary Islands, Spain.
- Department of Medical Oncology, Portuguese Institute of Oncology of Porto, Porto, Portugal.
- Department of Breast Surgery, Hokkaido University Hospital, Hokkaido, Japan.
Förderung
- Eli Lilly and Company
Zitieren
APA
Tolaney, S. M., Guarneri, V., Seo, J. H., Cruz, J., Abreu, M. H., Takahashi, M., Barrios, C., McIntyre, K., Wei, R., Munoz, M., Antonio, B. S., Liepa, A. M., Martin, M., Johnston, S. R. D., Kellokumpu-Lehtinen, P. L., & Harbeck, N. (2024). Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer. European Journal of Cancer, 199, 113555. https://doi.org/10.1016/j.ejca.2024.113555
Vancouver
Tolaney SM, Guarneri V, Seo JH, Cruz J, Abreu MH, Takahashi M, et al. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer. European Journal of Cancer. 2024;199:113555. doi:10.1016/j.ejca.2024.113555
BibTeX
@article{Tolaney2024,
author = {Tolaney, Sara M and Guarneri, Valentina and Seo, Jae Hong and Cruz, Josefina and Abreu, Miguel Henriques and Takahashi, Masato and Barrios, Carlos and McIntyre, Kristi and Wei, Ran and Munoz, Maria and Antonio, Belen San and Liepa, Astra M and Martin, Miguel and Johnston, Stephen R D and Kellokumpu-Lehtinen, Pirkko-Liisa and Harbeck, Nadia},
title = {Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer},
journal = {European Journal of Cancer},
year = {2024},
volume = {199},
pages = {113555},
doi = {10.1016/j.ejca.2024.113555}
}
EUVIMED